Bio-Rad Laboratories, Inc. (NYSE:BIO) shares traded up 3% during trading on Monday . The stock traded as high as $149.95 and last traded at $149.38, with a volume of 72,966 shares. The stock had previously closed at $145.09.

Several research analysts recently commented on the company. Zacks Investment Research raised Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th. Jefferies Group reiterated a “buy” rating on shares of Bio-Rad Laboratories in a research note on Wednesday, June 8th.

The company has a market capitalization of $4.37 billion and a PE ratio of 40.65. The stock has a 50-day moving average of $142.93 and a 200-day moving average of $138.24.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, May 5th. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by $0.18. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The company earned $471.20 million during the quarter, compared to analyst estimates of $463.90 million. The company’s revenue was down .3% compared to the same quarter last year. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post $3.40 EPS for the current fiscal year.

Several hedge funds and institutional investors have bought and sold shares of the company. Levin Capital Strategies L.P. raised its position in Bio-Rad Laboratories by 9.5% in the fourth quarter. Levin Capital Strategies L.P. now owns 689,214 shares of the company’s stock worth $95,566,000 after buying an additional 60,059 shares during the last quarter. Morgan Stanley raised its position in Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock worth $9,921,000 after buying an additional 55,884 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its position in Bio-Rad Laboratories by 3.0% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 396,376 shares of the company’s stock worth $54,961,000 after buying an additional 11,465 shares during the last quarter. BlackRock Advisors LLC raised its position in Bio-Rad Laboratories by 4.7% in the fourth quarter. BlackRock Advisors LLC now owns 114,344 shares of the company’s stock worth $15,855,000 after buying an additional 5,085 shares during the last quarter. Finally, Liberty Mutual Group Asset Management Inc. raised its position in Bio-Rad Laboratories by 51.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,320 shares of the company’s stock worth $1,846,000 after buying an additional 4,523 shares during the last quarter.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.